Sphingolipid players in the leukemia arena

Biochimica et Biophysica Acta - Biomembranes

Volumn 1758, Issue 12, 2006, Pages 2121-2132

  Ricci, Clara ^a,b   Onida, Francesco ^b,c   Ghidoni, Riccardo ^a  

^a SAN PAOLO HOSPITAL   (Italy)

^b Fondazione Matarelli   (Italy)

^c FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

Author keywords

Apoptosis; Ceramide; Chemotherapeutics; Leukemia; Resistance; Sphingolipids

Indexed keywords

ANTINEOPLASTIC AGENTS; HUMANS; LEUKEMIA; SPHINGOLIPIDS;

EID: 33845284855     PISSN: 00052736     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbamem.2006.06.016     Document Type: Review

References (123)

1. Cuvillier O., Pirianov G., Kleuser B., Vanek P.G., Coso O.A., Gutkind S., and Spiegel S. Suppression of ceramide-mediated programmed cell death by sphingosine-1-phosphate. Nature 381 (1996) 800-803
2. Cuvillier O., and Levade T. Sphingosine 1-phosphate antagonizes apoptosis of human leukemia cells by inhibiting release of cytochrome c and Smac/DIABLO from mitochondria. Blood 98 (2001) 2828-2836
3. Spiegel S. Sphingosine 1-phosphate: a prototype of a new class of second messengers. J. Leukoc. Biol. 65 (1999) 341-344
4. Radin N.S. Killing cancer cells by poly-drug elevation of ceramide levels: a hypothesis whose time has come?. Eur. J. Biochem. 268 (2001) 193-204
5. Spiegel S., and Kolesnick R. Sphingosine 1-phosphate as a therapeutic agent. Leukemia 16 (2002) 1596-1602
6. Radin N.S. Killing tumours by ceramide-induced apoptosis: a critique of available drugs. Biochem. J. 371 (2003) 243-256
7. Ogretmen B., and Hannun Y.A. Biologically active sphingolipids in cancer pathogenesis and treatment. Nat. Rev., Cancer 4 (2004) 604-616
8. Sawai H., Domae N., and Okazaki T. Current status and perspectives in ceramide-targeting molecular medicine. Curr. Pharm. Des. 11 (2005) 2479-2487
9. Okazaki T., Kondo T., Kitano T., and Tashima M. Diversity and complexity of ceramide signalling in apoptosis. Cell Signalling 10 (1998) 685-692
10. Ho A.D. Kinetics and symmetry of divisions of hematopoietic stem cells. Exp. Hematol. 33 (2005) 1-8
11. Reya T., Morrison S.J., Clarke M.F., and Weissman I.L. Stem cells, cancer, and cancer stem cells. Nature 414 (2001) 105-111
12. Passegue E., Jamieson C.H., Ailles L.E., and Weissman I.L. Normal and leukemic hematopoiesis: are leukemias a stem cell disorder or a reacquisition of stem cell characteristics?. Proc. Natl. Acad. Sci. U. S. A. 1 (2003) 11842-11849
13. Harris N.L., Jaffe E.S., Stein H., Banks P.M., Chan J.K., Cleary M.L., Delsol G., De Wolf-Peeters C., Falini B., Gatter K.C., et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 84 (1994) 1361-1392
14. Bennett J.M., Catovsky D., Daniel M.T., Flandrin G., Galton D.A., Gralnick H.R., and Sultan C. Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group. Br. J. Haematol. 33 (1976) 451-458
15. Bennett J.M., Catovsky D., Daniel M.T., Flandrin G., Galton D.A., Gralnick H.R., and Sultan C. Proposals for the classification of the myelodysplastic syndromes. Br. J. Haematol. 51 (1982) 189-199
16. Berlin N.I. Diagnosis and classification of the polycythemias. Semin. Hematol. 12 (1975) 339-351
17. Murphy S., Peterson P., Iland H., and Laszlo J. Experience of the Polycythemia Vera Study Group with essential thrombocythemia: a final report on diagnostic criteria, survival, and leukemic transition by treatment. Semin. Hematol. 34 (1997) 29-39
18. Vardiman J.W., Harris N.L., and Brunning R.D. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 100 (2002) 2292-2302
19. Frohling S., Scholl C., Gillil D.G., and Levine R.L. Genetics of myeloid malignancies: pathogenetic and clinical implications. J. Clin. Oncol. 23 (2005) 6285-6295
20. Bonnet D., and Dick J.E. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat. Med. 3 (1997) 730-737
21. Warner J.K., Wang J.C., Hope K.J., Jin L., and Dick J.E. Concepts of human leukemic development. Oncogene 23 (2004) 7164-7177
22. Jordan C.T., and Guzman M.L. Mechanisms controlling pathogenesis and survival of leukemic stem cells. Oncogene 23 (2004) 7178-7187
23. Bonnet D. Normal and leukaemic stem cells. Br. J. Haematol. 130 (2005) 469-479
24. Huntly B.J., and Gilliland D.G. Leukaemia stem cells and the evolution of cancer-stem-cell research. Nat. Rev., Cancer 5 (2005) 311-321
25. Elrick L.J., Jorgensen H.G., Mountford J.C., and Holyoake T.L. Punish the parent not the progeny. Blood 105 (2005) 1862-1866
26. Moore M.A. Converging pathways in leukemogenesis and stem cell self-renewal. Exp. Hematol. 33 (2005) 719-737
27. Holyoake T., Jiang X., Eaves C., and Eaves A. Isolation of a highly quiescent subpopulation of primitive leukemic cells in chronic myeloid leukemia. Blood 94 (1999) 2056-2064
28. Hope K.J., Jin L., and Dick J.E. Acute myeloid leukemia originates from a hierarchy of leukemic stem cell classes that differ in self-renewal capacity. Nat. Immunol. 5 (2004) 738-743
29. Faderl S., Talpaz M., Estrov Z., O'Brien S., Kurzrock R., and Kantarjian H.M. The biology of chronic myeloid leukemia. N. Engl. J. Med. 341 (1999) 164-172
30. Kantarjian H., Sawyers C., Hochhaus A., Guilhot F., Schiffer C., Gambacorti-Passerini C., Niederwieser D., Resta D., Capdeville R., Zoellner U., Talpaz M., Druker B., Goldman J., O'Brien S.G., Russell N., Fischer T., Ottmann O., Cony-Makhoul P., Facon T., Stone R., Miller C., Tallman M., Brown R., Schuster M., Loughran T., Gratwohl A., Mandelli F., Saglio G., Lazzarino M., Russo D., Baccarani M., and Morra E. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N. Engl. J. Med. 346 (2002) 645-652
31. Talpaz M., Silver R.T., Druker B.J., Goldman J.M., Gambacorti-Passerini C., Guilhot F., Schiffer C.A., Fischer T., Deininger M.W., Lennard A.L., Hochhaus A., Ottmann O.G., Gratwohl A., Baccarani M., Stone R., Tura S., Mahon F.X., Fernandes-Reese S., Gathmann I., Capdeville R., Kantarjian H.M., and Sawyers C.L. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood 99 (2002) 1928-1937
32. Kantarjian H.M., Cortes J., O'Brien S., Giles F.J., Albitar M., Rios M.B., Shan J., Faderl S., Garcia-Manero G., Thomas D.A., Resta D., and Talpaz M. Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase. Blood 99 (2002) 3547-3553
33. Gilliland D.G., Jordan C.T., and Felix C.A. The molecular basis of leukemia. Hematology (Am. Soc. Hematol. Educ. Program) (2004) 80-97
34. Gillil D.G., and Griffin J.D. The roles of FLT3 in hematopoiesis and leukemia. Blood 100 (2002) 1532-1542
35. Fiedler W., Mesters R., Tinnefeld H., Loges S., Staib P., Duhrsen U., Flasshove M., Ottmann O.G., Jung W., Cavalli F., Kuse R., Thomalla J., Serve H., O'Farrell A.M., Jacobs M., Brega N.M., Scigalla P., Hossfeld D.K., and Berdel W.E. A phase 2 clinical study of SU5416 in patients with refractory acute myeloid leukemia. Blood 102 (2003) 2763-2767
36. Smith B.D., Levis M., Beran M., Giles F., Kantarjian H., Berg K., Murphy K.M., Dauses T., Allebach J., and Small D. Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia. Blood 103 (2004) 3669-3676
37. Stone R.M., DeAngelo D.J., Klimek V., Galinsky I., Estey E., Nimer S.D., Grandin W., Lebwohl D., Wang Y., Cohen P., Fox E.A., Neuberg D., Clark J., Gillil D.G., and Griffin J.D. Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412. Blood 105 (2005) 54-60
38. Kitada S., Pedersen I.M., Schimmer A.D., and Reed J.C. Dysregulation of apoptosis genes in hematopoietic malignancies. Oncogene 21 (2002) 3459-3474
39. Kitada S., and Reed J.C. MCL-1 promoter insertions dial-up aggressiveness of chronic leukemia. J. Natl. Cancer Inst. 96 (2004) 642-643
40. Reed J.C., and Pellecchia M. Apoptosis-based therapies for hematologic malignancies. Blood 106 (2005) 408-418
41. Silverman L.R., Demakos E.P., Peterson B.L., Kornblith A.B., Holland J.C., Odchimar-Reissig R., Stone R.M., Nelson D., Powell B.L., DeCastro C.M., Ellerton J., Larson R.A., Schiffer C.A., and Holland J.F. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J. Clin. Oncol. 20 (2002) 2429-2440
42. McKenna S.L., and Padua R.A. Multidrug resistance in leukaemia. Br. J. Haematol. 96 (1997) 659-674
43. Hingorani S.R., and Tuveson D.A. Targeting oncogene dependence and resistance. Cancer Cell 3 (2003) 414-417
44. Daub H., Specht K., and Ullrich A. Strategies to overcome resistance to targeted protein kinase inhibitors. Nat. Rev., Drug Discov. 3 (2004) 1001-1010
45. Deininger M., Buchdunger E., and Druker B.J. The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood 105 (2005) 2640-2653
46. Costello R.T., Mallet F., Gaugler B., Sainty D., Arnoulet C., Gastaut J.A., and Olive D. Human acute myeloid leukemia CD34+/CD38- progenitor cells have decreased sensitivity to chemotherapy and Fas-induced apoptosis, reduced immunogenicity, and impaired dendritic cell transformation capacities. Cancer Res. 60 (2000) 4403-4411
47. Graham S.M., Jorgensen H.G., Allan E., Pearson C., Alcorn M.J., Richmond L., and Holyoake T.L. Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood 99 (2002) 319-325
48. Guzman M.L., Neering S.J., Upchurch D., Grimes B., Howard D.S., Rizzieri D.A., Luger S.M., and Jordan C.T. Nuclear factor-kappaB is constitutively activated in primitive human acute myelogenous leukemia cells. Blood 98 (2001) 2301-2307
49. Herr I., Wilhelm D., Bohler T., Angel P., and Debatin K.M. Activation of CD95 (APO-1/Fas) signaling by ceramide mediates cancer therapy-induced apoptosis. EMBO J. 16 (1997) 6200-6208
50. El-Assaad W., Kozhaya L., Araysi S., Panjarian S., Bitar F.F., Baz E., El-Sabban M.E., and Dbaibo G.S. Ceramide and glutathione define two independently regulated pathways of cell death initiated by p53 in Molt-4 leukaemia cells. Biochem. J. 376 (2003) 725-732
51. Bruno A.P., Laurent G., Averbeck D., Demur C., Bonnet J., Bettaieb A., Levade T., and Jaffrezou J.P. Lack of ceramide generation in TF-1 human myeloid leukemic cells resistant to ionizing radiation. Cell Death Differ. 5 (1998) 172-182
52. Bonhoure E., Pchejetski D., Aouali N., Morjani H., Levade T., Kohama T., and Cuvillier O. Overcoming MDR-associated chemoresistance in HL-60 acute myeloid leukemia cells by targeting shingosine kinase-1. Leukemia 20 (2006) 95-102
53. Bose R., Verheij M., Haimovitz-Friedman A., Scotto K., Fuks Z., and Kolesnick R. Ceramide synthase mediates daunorubicin-induced apoptosis: an alternative mechanism for generating death signals. Cell 82 (1995) 405-414
54. Jaffrezou J.P., Levade T., Bettaieb A., Andrieu N., Bezombes C., Maestre N., Vermeersch S., Rousse A., and Laurent G. Daunorubicin-induced apoptosis: triggering of ceramide generation through sphingomyelin hydrolysis. EMBO J. 15 (1996) 2417-2424
55. Turnbull K.J., Brown B.L., and Dobson P.R. Caspase-3-like activity is necessary but not sufficient for daunorubicin-induced apoptosis in Jurkat human lymphoblastic leukemia cells. Leukemia 13 (1999) 1056-1061
56. Bezombes C., Plo I., Mansat-De Mas V., Quillet-Mary A., Negre-Salvayre A., Laurent G., and Jaffrezou J.P. Oxidative stress-induced activation of Lyn recruits sphingomyelinase and is requisite for its stimulation by Ara-C. FASEB J. 15 (2001) 1583-1585
57. Bezombes C., de Thonel A., Apostolou A., Louat T., Jaffrezou J.P., Laurent G., and Quillet-Mary A. Overexpression of protein kinase Czeta confers protection against antileukemic drugs by inhibiting the redox-dependent sphingomyelinase activation. Mol. Pharmacol. 62 (2002) 1446-1455
58. Biswal S.S., Datta K., Acquaah-Mensah G.K., and Kehrer J.P. Changes in ceramide and sphingomyelin following fludarabine treatment of human chronic B-cell leukemia cells. Toxicology 154 (2000) 45-53
59. Zhang J., Alter N., Reed J.C., Borner C., Obeid L.M., and Hannun Y.A. Bcl-2 interrupts the ceramide-mediated pathway of cell death. Proc. Natl. Acad. Sci. U. S. A. 93 (1996) 5325-5328
60. Olshefski R.S., and Ladisch S. Glucosylceramide synthase inhibition enhances vincristine-induced cytotoxicity. Int. J. Cancer 93 (2001) 131-138
61. Perry D.K., Carton J., Shah A.K., Meredith F., Uhlinger D.J., and Hannun Y.A. Serine palmitoyltransferase regulates de novo ceramide generation during etoposide-induced apoptosis. J. Biol. Chem. 275 (2000) 9078-9084
62. Dipietrantonio A., Hsieh T.C., and Wu J.M. Differential effects of retinoic acid (RA) and N-(4-hydroxyphenyl) retinamide (4-HPR) on cell growth, induction of differentiation, and changes in p34cdc2, Bcl-2, and actin expression in the human promyelocytic HL-60 leukemic cells. Biochem. Biophys. Res. Commun. 224 (1996) 837-842
63. DiPietrantonio A.M., Hsieh T.C., Olson S.C., and Wu J.M. Regulation of G1/S transition and induction of apoptosis in HL-60 leukemia cells by fenretinide (4HPR). Int. J. Cancer 78 (1998) 53-61
64. Laethem R.M., Hannun Y.A., Jayadev S., Sexton C.J., Strum J.C., Sundseth R., and Smith G.K. Increases in neutral, Mg2+-dependent and acidic, Mg2+-independent sphingomyelinase activities precede commitment to apoptosis and are not a consequence of caspase 3-like activity in Molt-4 cells in response to thymidylate synthase inhibition by GW1843. Blood 91 (1998) 4350-4360
65. Senchenkov A., Han T.Y., Wang H., Frankel A.E., Kottke T.J., Kaufmann S.H., and Cabot M.C. Enhanced ceramide generation and induction of apoptosis in human leukemia cells exposed to DT(388)-granulocyte-macrophage colony-stimulating factor (GM-CSF), a truncated diphtheria toxin fused to human GM-CSF. Blood 98 (2001) 1927-1934
66. Rahmani M., Reese E., Dai Y., Bauer C., Payne S.G., Dent P., Spiegel S., and Grant S. Coadministration of histone deacetylase inhibitors and perifosine synergistically induces apoptosis in human leukemia cells through Akt and ERK1/2 inactivation and the generation of ceramide and reactive oxygen species. Cancer Res. 65 (2005) 2422-2432
67. Rosato R.R., Maggio S.C., Almenara J.A., Payne S.G., Atadja P., Spiegel S., Dent P., and Grant S. The histone deacetylase inhibitor LAQ-824 induces human leukemia cell death through a process involving XIAP down-regulation, oxidative injury, and the acid sphingomyelinase-dependent generation of ceramide. Mol. Pharmacol. 69 (2006) 216-225
68. Murate T., Suzuki M., Hattori M., Takagi A., Kojima T., Tanizawa T., Asano H., Hotta T., Saito H., Yoshida S., and Tamiya-Koizumi K. Up-regulation of Acid Sphingomyelinase during retinoic acid-induced myeloid differentiation of NB4, a human acute promyelocytic leukemia cell line. J. Biol. Chem. 277 (2002) 9936-9943
69. Minamino M., Sakaguchi I., Naka T., Ikeda N., Kato Y., Tomiyasu I., Yano I., and Kobayashi K. Bacterial ceramides and sphingophospholipids induce apoptosis of human leukaemic cells. Microbiology 149 (2003) 2071-2081
70. Obeid L.M., Linardic C.M., Karolak L.A., and Hannun Y.A. Programmed cell death induced by ceramide. Science 259 (1993) 1769-1771
71. Myrick D., Blackinton D., Klostergaard J., Kouttab N., Maizel A., Wanebo H., and Mehta S. Paclitaxel-induced apoptosis in Jurkat, a leukemic T cell line, is enhanced by ceramide. Leuk. Res. 23 (1999) 569-578
72. Jarvis W.D., Kolesnick R.N., Fornari F.A., Traylor R.S., Gewirtz D.A., and Grant S. Induction of apoptotic DNA damage and cell death by activation of the sphingomyelin pathway. Proc. Natl. Acad. Sci. U. S. A. 91 (1994) 73-77
73. Baek M.Y., Yoo H.S., Nakaya K., Moon D.C., and Lee Y.M. Sphingolipid metabolic changes during chiral C2-ceramides induced apoptosis in human leukemia cells. Arch. Pharm. Res. 24 (2001) 144-149
74. Jayadev S., Liu B., Bielawska A.E., Lee J.Y., Nazaire F., Pushkareva M., Obeid L.M., and Hannun Y.A. Role for ceramide in cell cycle arrest. J. Biol. Chem. 270 (1995) 2047-2052
75. Ohta H., Sweeney E.A., Masamune A., Yatomi Y., Hakomori S., and Igarashi Y. Induction of apoptosis by sphingosine in human leukemic HL-60 cells: a possible endogenous modulator of apoptotic DNA fragmentation occurring during phorbol ester-induced differentiation. Cancer Res. 55 (1995) 691-697
76. Jarvis W.D., Fornari F.A., Traylor R.S., Martin H.A., Kramer L.B., Erukulla R.K., Bittman R., and Grant S. Induction of apoptosis and potentiation of ceramide-mediated cytotoxicity by sphingoid bases in human myeloid leukemia cells. J. Biol. Chem. 271 (1996) 8275-8284
77. Liu B., Andrieu-Abadie N., Levade T., Zhang P., Obeid L.M., and Hannun Y.A. Glutathione regulation of neutral sphingomyelinase in tumor necrosis factor-alpha-induced cell death. J. Biol. Chem. 273 (1998) 11313-11320
78. Andrieu-Abadie N., Gouaze V., Salvayre R., and Levade T. Ceramide in apoptosis signaling: relationship with oxidative stress. Free Radic. Biol. Med. 31 (2001) 717-728
79. Quillet-Mary A., Jaffrezou J.P., Mansat V., Bordier C., Naval J., and Laurent G. Implication of mitochondrial hydrogen peroxide generation in ceramide-induced apoptosis. J. Biol. Chem. 272 (1997) 21388-21395
80. Iwai K., Kondo T., Watanabe M., Yabu T., Kitano T., Taguchi Y., Umehara H., Takahashi A., Uchiyama T., and Okazaki T. Ceramide increases oxidative damage due to inhibition of catalase by caspase-3-dependent proteolysis in HL-60 cell apoptosis. J. Biol. Chem. 278 (2003) 9813-9822
81. Phillips D.C., Allen K., and Griffiths H.R. Synthetic ceramides induce growth arrest or apoptosis by altering cellular redox status. Arch. Biochem. Biophys. 407 (2002) 15-24
82. Chen M., Quintans J., Fuks Z., Thompson C., Kufe D.W., and Weichselbaum R.R. Suppression of Bcl-2 messenger RNA production may mediate apoptosis after ionizing radiation, tumor necrosis factor alpha, and ceramide. Cancer Res. 55 (1995) 991-994
83. Smyth M.J., Perry D.K., Zhang J., Poirier G.G., Hannun Y.A., and Obeid L.M. prICE: a downstream target for ceramide-induced apoptosis and for the inhibitory action of Bcl-2. Biochem. J. 316 Pt 1 (1996) 25-28
84. Geley S., Hartmann B.L., and Kofler R. Ceramides induce a form of apoptosis in human acute lymphoblastic leukemia cells that is inhibited by Bcl-2, but not by CrmA. FEBS Lett. 400 (1997) 15-18
85. Jaffrezou J.P., Maestre N., de Mas-Mansat V., Bezombes C., Levade T., and Laurent G. Positive feedback control of neutral sphingomyelinase activity by ceramide. FASEB J. 12 (1998) 999-1006
86. Nishizuka Y. Intracellular signaling by hydrolysis of phospholipids and activation of protein kinase C. Science 258 (1992) 607-614
87. Sawai H., Okazaki T., Takeda Y., Tashima M., Sawada H., Okuma M., Kishi S., Umehara H., and Domae N. Ceramide-induced translocation of protein kinase C-delta and -epsilon to the cytosol. Implications in apoptosis. J. Biol. Chem. 272 (1997) 2452-2458
88. Sawai H., Okazaki T., and Domae N. Sphingosine-induced c-jun expression: differences between sphingosine- and C2-ceramide-mediated signaling pathways. FEBS Lett. 524 (2002) 103-106
89. Sawai H., Okazaki T., Yamamoto H., Okano H., Takeda Y., Tashima M., Sawada H., Okuma M., Ishikura H., Umehara H., et al. Requirement of AP-1 for ceramide-induced apoptosis in human leukemia HL-60 cells. J. Biol. Chem. 270 (1995) 27326-27331
90. Jarvis W.D., Fornari Jr. F.A., Auer K.L., Freemerman A.J., Szabo E., Birrer M.J., Johnson C.R., Barbour S.E., Dent P., and Grant S. Coordinate regulation of stress- and mitogen-activated protein kinases in the apoptotic actions of ceramide and sphingosine. Mol. Pharmacol. 52 (1997) 935-947
91. Macchia M., Barontini S., Bertini S., Di Bussolo V., Fogli S., Giovannetti E., Grossi E., Minutolo F., and Danesi R. Design, synthesis, and characterization of the antitumor activity of novel ceramide analogues. J. Med. Chem. 44 (2001) 3994-4000
92. Shikata K., Niiro H., Azuma H., Ogino K., and Tachibana T. Apoptotic activities of C2-ceramide and C2-dihydroceramide homologues against HL-60 cells. Bioorg. Med. Chem. 11 (2003) 2723-2728
93. Kishida E., Kasahara M., Takagi Y., Matsumura M., Hayashi T., Kobayashi S., and Masuzawa Y. Evaluation of a trans configuration for the apoptosis-inducing activity of ceramide. J. Lipid Mediators Cell Signal. 16 (1997) 127-137
94. De Jonghe S., Van Overmeire I., Gunst J., De Bruyn A., Hendrix C., Van Calenbergh S., Busson R., De Keukeleire D., Philippe J., and Herdewijn P. Synthesis and apoptogenic activity of fluorinated ceramide and dihydroceramide analogues. Bioorg. Med. Chem. Lett. 9 (1999) 3159-3164
95. Bielawska A., Linardic C.M., and Hannun Y.A. Ceramide-mediated biology. Determination of structural and stereospecific requirements through the use of N-acyl-phenylaminoalcohol analogs. J. Biol. Chem. 267 (1992) 18493-18497
96. Wieder T., Geilen C.C., Kolter T., Sadeghlar F., Sandhoff K., Brossmer R., Ihrig P., Perry D., Orfanos C.E., and Hannun Y.A. Bcl-2 antagonizes apoptotic cell death induced by two new ceramide analogues. FEBS Lett. 411 (1997) 260-264
97. Karasavvas N., Erukulla R.K., Bittman R., Lockshin R., and Zakeri Z. Stereospecific induction of apoptosis in U937 cells by N-octanoyl-sphingosine stereoisomers and N-octyl-sphingosine. The ceramide amide group is not required for apoptosis. Eur. J. Biochem. 236 (1996) 729-737
98. Azuma H., Takao R., Shikata K., Niiro H., Tachibana T., and Ogino K. Synthesis and potent antileukemic activities of N-lactylsphingosine and N-lactyldihydrosphingosine. J. Med. Chem. 46 (2003) 3445-3447
99. Dagan A., Wang C., Fibach E., and Gatt S. Synthetic, non-natural sphingolipid analogs inhibit the biosynthesis of cellular sphingolipids, elevate ceramide and induce apoptotic cell death. Biochim. Biophys. Acta 1633 (2003) 161-169
100. Johnson C.R., Chun J., Bittman R., and Jarvis W.D. Intrinsic cytotoxicity and chemomodulatory actions of novel phenethylisothiocyanate sphingoid base derivatives in HL-60 human promyelocytic leukemia cells. J. Pharmacol. Exp. Ther. 309 (2004) 452-461
101. Cuvillier O., and Levade T. Enzymes of sphingosine metabolism as potential pharmacological targets for therapeutic intervention in cancer. Pharmacol. Res. 47 (2003) 439-445
102. Kok J.W., and Sietsma H. Sphingolipid metabolism enzymes as targets for anticancer therapy. Curr. Drug Targets 5 (2004) 375-382
103. Bielawska A., Greenberg M.S., Perry D., Jayadev S., Shayman J.A., McKay C., and Hannun Y.A. (1S,2R)-d-erythro-2-(N-myristoylamino)-1-phenyl-1-propanol as an inhibitor of ceramidase. J. Biol. Chem. 271 (1996) 12646-12654
104. Le Scolan E., Pchejetski D., Banno Y., Denis N., Mayeux P., Vainchenker W., Levade T., and Moreau-Gachelin F. Overexpression of sphingosine kinase 1 is an oncogenic event in erythroleukemic progression. Blood 106 (2005) 1808-1816
105. Olivera A., Kohama T., Edsall L., Nava V., Cuvillier O., Poulton S., and Spiegel S. Sphingosine kinase expression increases intracellular sphingosine-1-phosphate and promotes cell growth and survival. J. Cell Biol. 147 (1999) 545-558
106. Edsall L.C., Van Brocklyn J.R., Cuvillier O., Kleuser B., and Spiegel S. N,N-dimethylsphingosine is a potent competitive inhibitor of sphingosine kinase but not of protein kinase C: modulation of cellular levels of sphingosine 1-phosphate and ceramide. Biochemistry 37 (1998) 12892-12898
107. Jendiroba D.B., Klostergaard J., Keyhani A., Pagliaro L., and Freireich E.J. Effective cytotoxicity against human leukemias and chemotherapy-resistant leukemia cell lines by N-N-dimethylsphingosine. Leuk. Res. 26 (2002) 301-310
108. French K.J., Schrecengost R.S., Lee B.D., Zhuang Y., Smith S.N., Eberly J.L., Yun J.K., and Smith C.D. Discovery and evaluation of inhibitors of human sphingosine kinase. Cancer Res. 63 (2003) 5962-5969
109. Kono K., Tanaka M., Ogita T., Hosoya T., and Kohama T. F-12509A, a new sphingosine kinase inhibitor, produced by a discomycete. J. Antibiot. (Tokyo) 53 (2000) 459-466
110. Kono K., Sugiura M., and Kohama T. Inhibition of recombinant sphingosine kinases by novel inhibitors of microbial origin, F-12509A and B-5354c. J. Antibiot. (Tokyo) 55 (2002) 99-103
111. Meng A., Luberto C., Meier P., Bai A., Yang X., Hannun Y.A., and Zhou D. Sphingomyelin synthase as a potential target for D609-induced apoptosis in U937 human monocytic leukemia cells. Exp. Cell Res. 292 (2004) 385-392
112. Bai A., Meier G.P., Wang Y., Luberto C., Hannun Y.A., and Zhou D. Prodrug modification increases potassium tricyclo[5.2.1.0(2,6)]-decan-8-yl dithiocarbonate (D609) chemical stability and cytotoxicity against U937 leukemia cells. J. Pharmacol. Exp. Ther. 309 (2004) 1051-1059
113. van Helvoort A., Smith A.J., Sprong H., Fritzsche I., Schinkel A.H., Borst P., and van Meer G. MDR1 P-glycoprotein is a lipid translocase of broad specificity, while MDR3 P-glycoprotein specifically translocates phosphatidylcholine. Cell 87 (1996) 507-517
114. vanHelvoort A., Giudici M.L., Thielemans M., and van Meer G. Transport of sphingomyelin to the cell surface is inhibited by brefeldin A and in mitosis, where C6-NBD-sphingomyelin is translocated across the plasma membrane by a multidrug transporter activity. J. Cell Sci. 110 Pt. 1 (1997) 75-83
115. Bettaieb A., Record M., Come M.G., Bras A.C., Chap H., Laurent G., and Jaffrezou J.P. Opposite effects of tumor necrosis factor alpha on the sphingomyelin-ceramide pathway in two myeloid leukemia cell lines: role of transverse sphingomyelin distribution in the plasma membrane. Blood 88 (1996) 1465-1472
116. Bezombes C., Maestre N., Laurent G., Levade T., Bettaieb A., and Jaffrezou J.P. Restoration of TNF-alpha-induced ceramide generation and apoptosis in resistant human leukemia KG1a cells by the P-glycoprotein blocker PSC833. FASEB J. 12 (1998) 101-109
117. Pallis M., and Russell N. P-glycoprotein plays a drug-efflux-independent role in augmenting cell survival in acute myeloblastic leukemia and is associated with modulation of a sphingomyelin-ceramide apoptotic pathway. Blood 95 (2000) 2897-2904
118. Lala P., Ito S., and Lingwood C.A. Retroviral transfection of Madin-Darby canine kidney cells with human MDR1 results in a major increase in globotriaosylceramide and 10(5)- to 10(6)-fold increased cell sensitivity to verocytotoxin. Role of p-glycoprotein in glycolipid synthesis. J. Biol. Chem. 275 (2000) 6246-6251
119. Shabbits J.A., and Mayer L.D. P-glycoprotein modulates ceramide-mediated sensitivity of human breast cancer cells to tubulin-binding anticancer drugs. Mol. Cancer Ther. 1 (2002) 205-213
120. De Rosa M.F., Sillence D., Ackerley C., and Lingwood C. Role of multiple drug resistance protein 1 in neutral but not acidic glycosphingolipid biosynthesis. J. Biol. Chem. 279 (2004) 7867-7876
121. Turzanski J., Grundy M., Shang S., Russell N., and Pallis M. P-glycoprotein is implicated in the inhibition of ceramide-induced apoptosis in TF-1 acute myeloid leukemia cells by modulation of the glucosylceramide synthase pathway. Exp. Hematol. 33 (2005) 62-72
122. Itoh M., Kitano T., Watanabe M., Kondo T., Yabu T., Taguchi Y., Iwai K., Tashima M., Uchiyama T., and Okazaki T. Possible role of ceramide as an indicator of chemoresistance: decrease of the ceramide content via activation of glucosylceramide synthase and sphingomyelin synthase in chemoresistant leukemia. Clin. Cancer Res. 9 (2003) 415-423
123. Liu B., and Hannun Y.A. Inhibition of the neutral magnesium-dependent sphingomyelinase by glutathione. J. Biol. Chem. 272 (1997) 16281-16287